| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial
|
Nair, Gonasagrie
|
|
|
|
12 |
p. e779-e789
|
artikel
|
| 2 |
Adolescent participation in HIV research: consortium experience in low and middle-income countries and scoping review
|
Day, Suzanne
|
|
|
|
12 |
p. e844-e852
|
artikel
|
| 3 |
Adolescents key to achieving HIV control targets in Uganda
|
Nakkazi, Esther
|
|
|
|
12 |
p. e681-e682
|
artikel
|
| 4 |
Age-specific associations between HIV infection and carotid artery intima-media thickness in China: a cross-sectional evaluation of baseline data from the CHART cohort
|
Lin, Haijiang
|
|
|
|
12 |
p. e860-e868
|
artikel
|
| 5 |
A new approach to cognitive impairment in people with HIV
|
Nightingale, Sam
|
|
|
|
12 |
p. e815-e817
|
artikel
|
| 6 |
Are we shifting attrition downstream in the HIV cascade?
|
Fox, Matthew P
|
|
2016
|
|
12 |
p. e554-e555
nvt p.
|
artikel
|
| 7 |
ART and cardiovascular-disease risk in people with HIV
|
Malvestutto, Carlos
|
|
|
|
12 |
p. e760-e761
|
artikel
|
| 8 |
Association of pregnancy with engagement in HIV care among women with HIV in the UK: a cohort study
|
Okhai, Hajra
|
|
|
|
12 |
p. e747-e754
|
artikel
|
| 9 |
Barong: reaching out to where things happen in Brazil
|
Daniels, Joe Parkin
|
|
|
|
12 |
p. e806
|
artikel
|
| 10 |
BCN Checkpoint—sexual health services in Barcelona
|
Kirby, Tony
|
|
|
|
12 |
p. e826
|
artikel
|
| 11 |
Beyond HIV viral suppression: an African perspective
|
Serwadda, David Musoke
|
|
|
|
12 |
p. e812-e814
|
artikel
|
| 12 |
Birth HIV testing and paediatric treatment programmes
|
Goga, Ameena
|
|
|
|
12 |
p. e675-e676
|
artikel
|
| 13 |
Burden of living with HIV among men who have sex with men: a mixed-methods study
|
van Bilsen, Ward P H
|
|
|
|
12 |
p. e835-e843
|
artikel
|
| 14 |
Celebrity, the media, and HIV—not always easy bedfellows
|
The Lancet HIV,
|
|
2015
|
|
12 |
p. e501-
1 p.
|
artikel
|
| 15 |
Charting a course for public health leadership by cities on HIV, tuberculosis, and viral hepatitis
|
Zuniga, José M
|
|
|
|
12 |
p. e732-e733
|
artikel
|
| 16 |
Children affected by HIV need a holistic approach to care
|
The Lancet HIV,
|
|
|
|
12 |
p. e671
|
artikel
|
| 17 |
Committing to disability inclusion to end AIDS by 2030
|
Hanass-Hancock, Jill
|
|
2016
|
|
12 |
p. e556-e557
nvt p.
|
artikel
|
| 18 |
Control of epidemics by jails: lessons for COVID-19 from HIV
|
Ohuabunwa, Tochi
|
|
|
|
12 |
p. e798-e799
|
artikel
|
| 19 |
COP27 Climate Change Conference: urgent action needed for Africa and the world
|
Atwoli, Lukoye
|
|
|
|
12 |
p. e817-e819
|
artikel
|
| 20 |
Correction to Lancet HIV 2022; 9: e79–90
|
|
|
|
|
12 |
p. e822
|
artikel
|
| 21 |
Correction to Lancet HIV 2021; 8: e568–80
|
|
|
|
|
12 |
p. e822
|
artikel
|
| 22 |
Correction to Lancet HIV 2021; 8: e633–51
|
|
|
|
|
12 |
p. e822
|
artikel
|
| 23 |
Correction to Lancet HIV 2022; 9: e438–48
|
|
|
|
|
12 |
p. e822
|
artikel
|
| 24 |
Correction to Lancet HIV 2018; 5: e488–97
|
|
|
|
|
12 |
p. e822
|
artikel
|
| 25 |
Correction to Lancet HIV 2022; 9: e791–800
|
|
|
|
|
12 |
p. e822
|
artikel
|
| 26 |
Correction to Lancet HIV 2019; 6: e416–17
|
|
|
|
|
12 |
p. e815
|
artikel
|
| 27 |
Correction to Lancet HIV 2018; 5: e341
|
|
|
|
|
12 |
p. e815
|
artikel
|
| 28 |
Correction to Lancet HIV 2019; 6: e230–39
|
|
|
|
|
12 |
p. e815
|
artikel
|
| 29 |
Correction to Lancet HIV 2018; 6: e93–104
|
|
|
|
|
12 |
p. e815
|
artikel
|
| 30 |
Correction to Lancet HIV 2018; 5: e553–59
|
|
|
|
|
12 |
p. e815
|
artikel
|
| 31 |
Correction to Lancet HIV 2019; 6: e173–81
|
|
|
|
|
12 |
p. e815
|
artikel
|
| 32 |
Correction to Lancet HIV 2019; 6: e760–68
|
|
|
|
|
12 |
p. 815
|
artikel
|
| 33 |
Correction to Lancet HIV 2019; 6: e737–49
|
|
|
|
|
12 |
p. e803
|
artikel
|
| 34 |
Correction to Lancet HIV 2020; 7: e84
|
|
|
|
|
12 |
p. e803
|
artikel
|
| 35 |
Correction to Lancet HIV 2019; 6: e105–15
|
|
|
|
|
12 |
p. e803
|
artikel
|
| 36 |
Correction to Lancet HIV 2020; 7: e322–31
|
|
|
|
|
12 |
p. e803
|
artikel
|
| 37 |
Correction to Lancet HIV 2019; 6: e71–72
|
|
|
|
|
12 |
p. e803
|
artikel
|
| 38 |
Correction to Lancet HIV 2020; 7: e366–72
|
|
|
|
|
12 |
p. e803
|
artikel
|
| 39 |
Correction to Lancet HIV 2020; 7: e565–73
|
|
|
|
|
12 |
p. e734
|
artikel
|
| 40 |
Correction to Lancet HIV 2021; 8: e67–76
|
|
|
|
|
12 |
p. e734
|
artikel
|
| 41 |
Correction to Lancet HIV 2021; 8: e185–96
|
|
|
|
|
12 |
p. e734
|
artikel
|
| 42 |
Correction to Lancet HIV 2021; 8: e397–407
|
|
|
|
|
12 |
p. e734
|
artikel
|
| 43 |
Correction to Lancet HIV 2021; 8: e197–205
|
|
|
|
|
12 |
p. e734
|
artikel
|
| 44 |
Correction to Lancet HIV 2023; 10: e424–26
|
|
|
|
|
12 |
p. e762
|
artikel
|
| 45 |
Correction to Lancet HIV 2023; 10: e244–53
|
|
|
|
|
12 |
p. e762
|
artikel
|
| 46 |
Correction to Lancet HIV 2023; 10: e385–93
|
|
|
|
|
12 |
p. e762
|
artikel
|
| 47 |
Correction to Lancet HIV 2018; 5: e696–705
|
|
|
|
|
12 |
p. e762
|
artikel
|
| 48 |
Correction to Lancet HIV 2023; 10: e375–84
|
|
|
|
|
12 |
p. e762
|
artikel
|
| 49 |
Correction to Lancet HIV 2019; published online Aug 28. https://doi.org/10.1016/S2352-3018(19)30293-0
|
|
|
|
|
12 |
p. e815
|
artikel
|
| 50 |
Correction to Lancet HIV 2019; published online Aug 23. https://doi.org/10.1016/S2352-3018(19)30274-7
|
|
|
|
|
12 |
p. e815
|
artikel
|
| 51 |
Correction to Lancet HIV 2020; published online Feb 17. https://doi.org/10.1016/S2352-3018(20)30001-1
|
|
|
|
|
12 |
p. e803
|
artikel
|
| 52 |
Correction to Lancet HIV 2020; published online Jan 14. https://doi.org/10.1016/S2352-3018(19)30378-9
|
|
|
|
|
12 |
p. e803
|
artikel
|
| 53 |
COVID-19 threatens HIV care continuity in Brazil
|
Daniels, Joe Parkin
|
|
|
|
12 |
p. e804-e805
|
artikel
|
| 54 |
Delays and gaps in HIV programmes in Pakistan
|
Altaf, Arshad
|
|
|
|
12 |
p. e678-e679
|
artikel
|
| 55 |
Digital health to support early infant diagnosis of HIV
|
Lester, Richard T
|
|
|
|
12 |
p. e673-e674
|
artikel
|
| 56 |
Effect of implementation strategies on pre-exposure prophylaxis persistence among female sex workers in South Africa: an interrupted time series study
|
Rao, Amrita
|
|
|
|
12 |
p. e807-e815
|
artikel
|
| 57 |
Effects of implementing universal and rapid HIV treatment on initiation of antiretroviral therapy and retention in care in Zambia: a natural experiment using regression discontinuity
|
Mody, Aaloke
|
|
|
|
12 |
p. e755-e765
|
artikel
|
| 58 |
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
|
Stanley, Takara L
|
|
|
|
12 |
p. e821-e830
|
artikel
|
| 59 |
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
|
Landovitz, Raphael J
|
|
|
|
12 |
p. e767-e778
|
artikel
|
| 60 |
Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study
|
Olney, Jack J
|
|
2016
|
|
12 |
p. e592-e600
nvt p.
|
artikel
|
| 61 |
Evaluation of the HIV Infant Tracking System (HITSystem) to optimise quality and efficiency of early infant diagnosis: a cluster-randomised trial in Kenya
|
Finocchario-Kessler, Sarah
|
|
|
|
12 |
p. e696-e705
|
artikel
|
| 62 |
Fee for home delivery and monitoring of antiretroviral therapy for HIV infection compared with standard clinic-based services in South Africa: a randomised controlled trial
|
Barnabas, Ruanne V
|
|
|
|
12 |
p. e848-e856
|
artikel
|
| 63 |
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised controlled trial
|
Rodger, Alison J
|
|
|
|
12 |
p. e838-e847
|
artikel
|
| 64 |
From early alarm to gradual control of monkeypox
|
Kirby, Tony
|
|
|
|
12 |
p. e824-e825
|
artikel
|
| 65 |
GBD 2015 and HIV estimates from the Optima model
|
Kelly, Sherrie L
|
|
2016
|
|
12 |
p. e558-
1 p.
|
artikel
|
| 66 |
GBD 2015 and HIV estimates from the Optima model – Authors' reply
|
Wang, Haidong
|
|
2016
|
|
12 |
p. e558-e559
nvt p.
|
artikel
|
| 67 |
Gender-affirmative systems needed for PrEP implementation
|
Operario, Don
|
|
|
|
12 |
p. e799-e800
|
artikel
|
| 68 |
Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries
|
Han, Win Min
|
|
|
|
12 |
p. e766-e775
|
artikel
|
| 69 |
Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017
|
|
|
|
|
12 |
p. e831-e859
|
artikel
|
| 70 |
Highlights of HIV Drug Therapy 2022
|
Henderson, Richard
|
|
|
|
12 |
p. e823
|
artikel
|
| 71 |
Highlights of HIV Drug Therapy 2018
|
Hayward, Peter
|
|
|
|
12 |
p. e684
|
artikel
|
| 72 |
Highlights of HIVR4P 2018
|
Zuccala, Elizabeth
|
|
|
|
12 |
p. e683
|
artikel
|
| 73 |
Highlights of the 19th European AIDS Conference
|
Gonzalez-Lopez, Adrian
|
|
|
|
12 |
p. e763
|
artikel
|
| 74 |
HIV and tuberculosis in children: biology meets epidemiology
|
Seddon, James A
|
|
2015
|
|
12 |
p. e506-e507
nvt p.
|
artikel
|
| 75 |
HIV care continuum interventions for Black men who have sex with men in the USA
|
Goldhammer, Hilary
|
|
|
|
12 |
p. e776-e786
|
artikel
|
| 76 |
HIV controllers: to treat or not to treat? Is that the right question?
|
Noël, Nicolas
|
|
|
|
12 |
p. e878-e884
|
artikel
|
| 77 |
HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment
|
Sullivan, Ann K
|
|
|
|
12 |
p. e790-e806
|
artikel
|
| 78 |
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial
|
Deutsch, Madeline B
|
|
2015
|
|
12 |
p. e512-e519
nvt p.
|
artikel
|
| 79 |
HIV self-testing: from availability to strategic deployment
|
Rahib, Delphine
|
|
|
|
12 |
p. e811-e812
|
artikel
|
| 80 |
Home delivery of ART: could this be a reality in South Africa?
|
Pascoe, Sophie J S
|
|
|
|
12 |
p. e812-e814
|
artikel
|
| 81 |
How much could long-acting PrEP cost in South Africa?
|
Mudimu, Edinah
|
|
|
|
12 |
p. e814-e815
|
artikel
|
| 82 |
Improved labelling of antiretrovirals for paediatric use
|
Burger, David M
|
|
2016
|
|
12 |
p. e550-e551
nvt p.
|
artikel
|
| 83 |
Innovation is important, but so is access
|
The Lancet HIV,
|
|
|
|
12 |
p. e809
|
artikel
|
| 84 |
Innovations, adaptations, and accelerations in the delivery of HIV services during COVID-19
|
Murphy, Eamonn
|
|
|
|
12 |
p. e884-e886
|
artikel
|
| 85 |
Issues about periconception use of dolutegravir are reminiscent of early concerns about efavirenz
|
Black, Vivian
|
|
|
|
12 |
p. e732-e736
|
artikel
|
| 86 |
Living well with HIV
|
The Lancet HIV,
|
|
|
|
12 |
p. e807
|
artikel
|
| 87 |
Long-acting cabotegravir PrEP: a time for cautious optimism
|
Griffin, David WJ
|
|
|
|
12 |
p. e756-e757
|
artikel
|
| 88 |
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment
|
McGowan, Ian
|
|
2016
|
|
12 |
p. e569-e578
nvt p.
|
artikel
|
| 89 |
Long-lasting HIV suppression by combined immunotherapy
|
Jaworski, Juan P
|
|
|
|
12 |
p. e680
|
artikel
|
| 90 |
LVCT Health: implementing PrEP in Kenya
|
Ligami, Christabel
|
|
|
|
12 |
p. e766
|
artikel
|
| 91 |
Making the most of a fertile PrEP landscape
|
The Lancet HIV,
|
|
|
|
12 |
p. e755
|
artikel
|
| 92 |
12-month outcomes of HIV-infected infants identified at birth at one maternity site in Johannesburg, South Africa: an observational cohort study
|
Technau, Karl-Günter
|
|
|
|
12 |
p. e706-e714
|
artikel
|
| 93 |
Mortality in migrants living with HIV in western Europe (1997–2013): a collaborative cohort study
|
|
|
2015
|
|
12 |
p. e540-e549
nvt p.
|
artikel
|
| 94 |
Mortality in migrants with HIV in western Europe
|
Gill, M John
|
|
2015
|
|
12 |
p. e508-e509
nvt p.
|
artikel
|
| 95 |
Moving towards the global HIV 95% viral suppression target
|
Bessong, Pascal O
|
|
|
|
12 |
p. e731-e732
|
artikel
|
| 96 |
Naguru Teenage Information and Health Centre
|
Nakkazi, Esther
|
|
|
|
12 |
p. e685
|
artikel
|
| 97 |
National estimates and risk factors associated with early mother-to-child transmission of HIV after implementation of option B+: a cross-sectional analysis
|
Tippett Barr, Beth A
|
|
|
|
12 |
p. e688-e695
|
artikel
|
| 98 |
Next-generation sequencing and HIV drug resistance surveillance
|
Hamers, Raph L
|
|
2016
|
|
12 |
p. e553-e554
nvt p.
|
artikel
|
| 99 |
Obstacles to prescribers' initiation early antiretroviral therapy: a barrier to achieving 90-90-90 goals
|
Medland, Nicholas A
|
|
2016
|
|
12 |
p. e559-e560
nvt p.
|
artikel
|
| 100 |
Outcomes in children on raltegravir: a story of two halves
|
Collins, Intira Jeannie
|
|
|
|
12 |
p. e676-e678
|
artikel
|
| 101 |
Pandemics have psychosocial and sociocultural burdens
|
McDaid, Lisa
|
|
|
|
12 |
p. e801-e802
|
artikel
|
| 102 |
Patterns of post-partum HIV care engagement
|
Psaros, Christina
|
|
|
|
12 |
p. e730-e731
|
artikel
|
| 103 |
People ageing with HIV face an uncertain future
|
Burki, Talha
|
|
|
|
12 |
p. e816-e817
|
artikel
|
| 104 |
People at the margins are central to HIV responses
|
The Lancet HIV,
|
|
|
|
12 |
p. e797
|
artikel
|
| 105 |
PEPFAR: promises and pitfalls
|
Stirrups, Robert
|
|
|
|
12 |
p. e735
|
artikel
|
| 106 |
Perceived HIV stigma and HIV testing among men and women in rural Uganda: a population-based study
|
Kalichman, Seth C
|
|
|
|
12 |
p. e817-e824
|
artikel
|
| 107 |
Planning for PrEP: are national surveillance data sufficient?
|
Rutstein, Sarah E
|
|
|
|
12 |
p. e759-e760
|
artikel
|
| 108 |
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions
|
Mayer, Kenneth H
|
|
|
|
12 |
p. e816-e824
|
artikel
|
| 109 |
PrEParing for choice in a new era of HIV prevention
|
Graybill, Lauren A
|
|
|
|
12 |
p. e757-e758
|
artikel
|
| 110 |
PrEP awareness and engagement among transgender women in South Africa: a cross-sectional, mixed methods study
|
Poteat, Tonia
|
|
|
|
12 |
p. e825-e834
|
artikel
|
| 111 |
PrEP empowering female sex workers in Kenya
|
Ligami, Christabel
|
|
|
|
12 |
p. e764-e765
|
artikel
|
| 112 |
Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey
|
Ávila-Ríos, Santiago
|
|
2016
|
|
12 |
p. e579-e591
nvt p.
|
artikel
|
| 113 |
Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study
|
Turkova, Anna
|
|
2015
|
|
12 |
p. e530-e539
nvt p.
|
artikel
|
| 114 |
Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1
|
Jaworski, Juan P
|
|
|
|
12 |
p. e723-e731
|
artikel
|
| 115 |
Programme science: a route to effective coverage and population-level impact for HIV and sexually transmitted infection prevention
|
McClarty, Leigh M
|
|
|
|
12 |
p. e825-e834
|
artikel
|
| 116 |
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis
|
Jamieson, Lise
|
|
|
|
12 |
p. e857-e867
|
artikel
|
| 117 |
Reorienting health systems to care for people with HIV beyond viral suppression
|
Safreed-Harmon, Kelly
|
|
|
|
12 |
p. e869-e877
|
artikel
|
| 118 |
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial
|
Nachman, Sharon
|
|
|
|
12 |
p. e715-e722
|
artikel
|
| 119 |
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial
|
Gaur, Aditya H
|
|
2016
|
|
12 |
p. e561-e568
nvt p.
|
artikel
|
| 120 |
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
|
Elliott, Julian H
|
|
2015
|
|
12 |
p. e520-e529
nvt p.
|
artikel
|
| 121 |
Should HIV testing week be blood-borne-virus testing week?
|
Orkin, Chloe
|
|
2015
|
|
12 |
p. e510-e511
nvt p.
|
artikel
|
| 122 |
Tackling latency as a barrier to an HIV cure: what next?
|
Katlama, Christine
|
|
2015
|
|
12 |
p. e504-e505
nvt p.
|
artikel
|
| 123 |
Tackling stigma in the Welsh valleys
|
Burki, Talha
|
|
|
|
12 |
p. e820
|
artikel
|
| 124 |
Taking Malawi's option B+ programme from a B+ to an A+
|
Rosenberg, Nora E
|
|
|
|
12 |
p. e672-e673
|
artikel
|
| 125 |
Tesamorelin, liver fat, and NAFLD in the setting of HIV
|
Audsley, Jennifer
|
|
|
|
12 |
p. e808-e809
|
artikel
|
| 126 |
The allure of a simple story
|
The Lancet HIV,
|
|
2016
|
|
12 |
p. e549-
1 p.
|
artikel
|
| 127 |
The art of expanding HIV awareness
|
Martin, Colin
|
|
|
|
12 |
p. e687
|
artikel
|
| 128 |
The effect of providing women sustained access to HIV self-tests on male partner testing, couples testing, and HIV incidence in Kenya: a cluster-randomised trial
|
Thirumurthy, Harsha
|
|
|
|
12 |
p. e736-e746
|
artikel
|
| 129 |
The global burden of HIV and prospects for control
|
Pandey, Abhishek
|
|
|
|
12 |
p. e809-e811
|
artikel
|
| 130 |
The last Black man with HIV in San Francisco: the potential role of gentrification on HIV getting to zero achievements
|
Pagkas-Bather, Jade
|
|
|
|
12 |
p. e853-e856
|
artikel
|
| 131 |
The potential impact of country-level migration networks on HIV epidemics in sub-Saharan Africa: the case of Botswana
|
Okano, Justin T
|
|
|
|
12 |
p. e787-e792
|
artikel
|
| 132 |
The San Francisco model and the nurses of Ward 5B
|
Lucas, Catherine
|
|
|
|
12 |
p. e819
|
artikel
|
| 133 |
The Seeds Project
|
Burki, Talha
|
|
|
|
12 |
p. e818
|
artikel
|
| 134 |
This is a story about living—not dying
|
Ranscombe, Peter
|
|
|
|
12 |
p. e686
|
artikel
|
| 135 |
Time to change cardiovascular prevention in people with HIV
|
Martinez, Esteban
|
|
|
|
12 |
p. e811-e812
|
artikel
|
| 136 |
Time to end discriminatory laws against people with HIV
|
The Lancet HIV,
|
|
|
|
12 |
p. e729
|
artikel
|
| 137 |
Transitioning youth living with HIV to adult HIV care
|
Ayieko, James
|
|
|
|
12 |
p. e810-e811
|
artikel
|
| 138 |
Transition to independent care for youth living with HIV: a cluster randomised clinical trial
|
Njuguna, Irene N
|
|
|
|
12 |
p. e828-e837
|
artikel
|
| 139 |
Two-drug regimens for HIV treatment
|
Gibas, Kevin M
|
|
|
|
12 |
p. e868-e883
|
artikel
|
| 140 |
Unheard testimony
|
Burki, Talha
|
|
|
|
12 |
p. e827
|
artikel
|
| 141 |
Universal test-and-treat in Zambian and South African correctional facilities: a multisite prospective cohort study
|
Herce, Michael E
|
|
|
|
12 |
p. e807-e816
|
artikel
|
| 142 |
Uptake and effectiveness of PrEP for transgender women
|
Marshall, Brandon D L
|
|
2015
|
|
12 |
p. e502-e503
nvt p.
|
artikel
|
| 143 |
Use of mobile phone data in HIV epidemic control
|
Valdano, Eugenio
|
|
|
|
12 |
p. e820-e821
|
artikel
|
| 144 |
When is a PrEP candidate ready for phase 3?
|
Hendrix, Craig
|
|
2016
|
|
12 |
p. e551-e553
nvt p.
|
artikel
|
Tijdschrift beschrijving